NewsBenzingaNeurocrine Biosciences relève ses prévisions de ventes nettes du produit INGREZZA pour l’exercice 2026 de 2,825 milliards à 2,875 milliards de dollars à 2,900 milliards à 2,925 milliards de dollars Neurocrine Biosciences relève ses prévisions de ventes nettes du produit INGREZZA pour l’exercice 2026 de 2,825 milliards à 2,875 milliards de dollars à 2,900 milliards à 2,925 milliards de dollars Benzinga 2026.11.02 22:01 (GMT+0) Open on Benzinga Other news Binance Plans to Expand into Five Asian Markets Next Year, Focusing on South and Southeast Asia PancakeSwap rebrands as Pancake, CAKE token and contracts unchanged Top Wall Street Forecasters Revamp TJX Expectations Ahead Of Q3 Earnings Trump Reportedly Traded Over $97 Million Worth of Nvidia Stock in 2 Years — Elizabeth Warren Wants Congress to Force Him to ‘Divest’ A-Share Market Close: ChiNext Index Rebounds From Lows to Gain 0.85% as Shanghai-Shenzhen Turnover Hits New Low for the Year Nebius Shares Jump After Hours as Nvidia’s Strong Quarterly Numbers Lift AI Infrastructure Stocks
Trump Reportedly Traded Over $97 Million Worth of Nvidia Stock in 2 Years — Elizabeth Warren Wants Congress to Force Him to ‘Divest’
A-Share Market Close: ChiNext Index Rebounds From Lows to Gain 0.85% as Shanghai-Shenzhen Turnover Hits New Low for the Year